Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human...
Cancer
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and...
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at...
Tango Therapeutics Announces $80 million Private Placement Financing
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...
Join Healthcare Leaders and Innovators at MEDITECH LIVE
The conference invites executives and clinicians to collaborate and help shape a new era in healthcare.CANTON, Mass.--(BUSINESS WIRE)--MEDITECH will be...
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in...
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional...
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration expansions for...
Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr....
SS Innovations International Sells First SSi Mantra in the Middle East
The first international sale of the SSi Mantra was delivered to Dubai, United Arab Emirates Additional International Sales Expected FORT...
AlzeCure Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer’s
STOCKHOLM, SWEDEN / ACCESSWIRE / August 9, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Science & Humans (S&H) Welcomes Esteemed Canadian Endocrinologist & Geneticist Dr. Fady Hannah-Shmouni to Medical Advisory Board
MISSISSAUGA, ON / ACCESSWIRE / August 8, 2023 / Science & Humans (S&H), a health and wellness company focused on...
Establishment Labs Reports Record Second Quarter 2023 Financial Results
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,...
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in ChicagoChronic SCI cohort results expected in...
NeoGenomics Reports Second Quarter 2023 Results
Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)...
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
Advanced panel already generating six-figure pre-ordersNEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc....
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across...
Sensus Healthcare Announces New $3 Million Share Repurchase Program
BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...